Cargando…
CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
Patients with relapsed and/or refractory (R/R) follicular lymphoma (FL) and mantle cell lymphoma (MCL) have a poor prognosis with anticipated short progression-free and overall survivals. Two CD19-directed chimeric antigen receptor T-cell (CAR T) therapies are approved in the United States for R/R F...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761215/ https://www.ncbi.nlm.nih.gov/pubmed/36544864 http://dx.doi.org/10.1177/20406207221142133 |
_version_ | 1784852660631896064 |
---|---|
author | Mohty, Razan Kharfan-Dabaja, Mohamed A. |
author_facet | Mohty, Razan Kharfan-Dabaja, Mohamed A. |
author_sort | Mohty, Razan |
collection | PubMed |
description | Patients with relapsed and/or refractory (R/R) follicular lymphoma (FL) and mantle cell lymphoma (MCL) have a poor prognosis with anticipated short progression-free and overall survivals. Two CD19-directed chimeric antigen receptor T-cell (CAR T) therapies are approved in the United States for R/R FL, namely, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel. The results of ZUMA-5 and ELARA studies led to the approval of axi-cel and tisagenlecleucel, respectively, after demonstrating high overall (ORR) and complete response (CR) rates in this high-risk population of FL patients who had received a median of 3 (range = 2–4) and 4 (range = 2–13) prior lines of therapies, respectively. For instance, the ORR for ZUMA-5 was 94% (CR = 79%), and for ELARA, it was 86% (CR = 69.1%). Pertaining to MCL, brexucabtagene autoleucel is approved for R/R MCL based on results of the ZUMA-2 study. In the latter study, despite the fact that all R/R MCL patients had been exposed to prior Bruton’s tyrosine kinase inhibitors, the reported ORR was 91%, with 68% achieving a CR. These results undoubtedly demonstrate a strong efficacy of CAR T therapy in both R/R FL and MCL; yet, one must acknowledge the relatively short follow-up time of all aforementioned studies. Thus, longer follow-up showing durability of responses and long-term safety is definitely needed. |
format | Online Article Text |
id | pubmed-9761215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-97612152022-12-20 CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma Mohty, Razan Kharfan-Dabaja, Mohamed A. Ther Adv Hematol Recent Advances in Immunotherapy for Lymphoma and Multiple Myeloma Patients with relapsed and/or refractory (R/R) follicular lymphoma (FL) and mantle cell lymphoma (MCL) have a poor prognosis with anticipated short progression-free and overall survivals. Two CD19-directed chimeric antigen receptor T-cell (CAR T) therapies are approved in the United States for R/R FL, namely, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel. The results of ZUMA-5 and ELARA studies led to the approval of axi-cel and tisagenlecleucel, respectively, after demonstrating high overall (ORR) and complete response (CR) rates in this high-risk population of FL patients who had received a median of 3 (range = 2–4) and 4 (range = 2–13) prior lines of therapies, respectively. For instance, the ORR for ZUMA-5 was 94% (CR = 79%), and for ELARA, it was 86% (CR = 69.1%). Pertaining to MCL, brexucabtagene autoleucel is approved for R/R MCL based on results of the ZUMA-2 study. In the latter study, despite the fact that all R/R MCL patients had been exposed to prior Bruton’s tyrosine kinase inhibitors, the reported ORR was 91%, with 68% achieving a CR. These results undoubtedly demonstrate a strong efficacy of CAR T therapy in both R/R FL and MCL; yet, one must acknowledge the relatively short follow-up time of all aforementioned studies. Thus, longer follow-up showing durability of responses and long-term safety is definitely needed. SAGE Publications 2022-12-16 /pmc/articles/PMC9761215/ /pubmed/36544864 http://dx.doi.org/10.1177/20406207221142133 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Recent Advances in Immunotherapy for Lymphoma and Multiple Myeloma Mohty, Razan Kharfan-Dabaja, Mohamed A. CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma |
title | CAR T-cell therapy for follicular lymphoma and mantle cell
lymphoma |
title_full | CAR T-cell therapy for follicular lymphoma and mantle cell
lymphoma |
title_fullStr | CAR T-cell therapy for follicular lymphoma and mantle cell
lymphoma |
title_full_unstemmed | CAR T-cell therapy for follicular lymphoma and mantle cell
lymphoma |
title_short | CAR T-cell therapy for follicular lymphoma and mantle cell
lymphoma |
title_sort | car t-cell therapy for follicular lymphoma and mantle cell
lymphoma |
topic | Recent Advances in Immunotherapy for Lymphoma and Multiple Myeloma |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761215/ https://www.ncbi.nlm.nih.gov/pubmed/36544864 http://dx.doi.org/10.1177/20406207221142133 |
work_keys_str_mv | AT mohtyrazan cartcelltherapyforfollicularlymphomaandmantlecelllymphoma AT kharfandabajamohameda cartcelltherapyforfollicularlymphomaandmantlecelllymphoma |